[HTML][HTML] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific reports, 2022 - nature.com
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - 2022 - researchsquare.com
Background Osimertinib was a third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific Reports, 2022 - ui.adsabs.harvard.edu
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
[HTML][HTML] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific Reports, 2022 - ncbi.nlm.nih.gov
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
[PDF][PDF] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - scholar.archive.org
Background Osimertinib was a third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific Reports, 2022 - europepmc.org
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific reports, 2022 - pubmed.ncbi.nlm.nih.gov
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Y Yin, Y Shu, J Zhu, F Li, J Li - Scientific Reports, 2022 - search.ebscohost.com
Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …
[PDF][PDF] A real‑world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
US Food - Scientific Reports, 2022 - d-nb.info
Results General characteristics. The clinical characteristics of osimertinib-associated AEs
were described in Table 1. For gender, the incidence of AEs in females (55.45%) accounted …
were described in Table 1. For gender, the incidence of AEs in females (55.45%) accounted …
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Osimertinib
Y Yin, Y Shu, J Zhu, F Li, J Li - 2022 - europepmc.org
Background: Osimertinib was a third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …
receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug …